Seres Therapeutics will present at the J.P. Morgan Healthcare Conference, focusing on SER-155's potential to reduce bloodstream infections.
Quiver AI Summary
Seres Therapeutics, Inc. has announced that CEO Eric Shaff will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, where the company will highlight its plans to advance its biotherapeutics pipeline, specifically focusing on SER-155. This program has received Breakthrough Therapy designation from the FDA for reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplants. SER-155 showed significant clinical benefits in a Phase 1b study, including a 77% relative risk reduction in infections. Seres is looking for partners to support the development of SER-155 and other pipeline programs targeting various medically vulnerable populations. The presentation will be available for live streaming and replay on the company’s website.
Potential Positives
- Seres Therapeutics announced that SER-155 received Breakthrough Therapy designation from the FDA, highlighting its potential to significantly reduce bloodstream infections in vulnerable patient populations.
- The company will present its corporate overview at the prestigious J.P. Morgan Healthcare Conference, which may enhance visibility and attract potential partnerships.
- SER-155 demonstrated a substantial 77% relative risk reduction in BSIs during clinical trials, indicating strong efficacy that may lead to improved patient outcomes.
- Seres aims to develop SER-155 for multiple medically vulnerable populations beyond allo-HSCT, expanding its market potential and therapeutic impact.
Potential Negatives
- The company has incurred significant losses and is not currently profitable, raising concerns about its financial stability and future viability.
- Seres is seeking a partner to provide financial resources and other capabilities, indicating potential resource constraints and dependency on external support for growth.
- The press release highlights multiple risks, including the uncertainty around the impact of the VOWST sale on operations, which may affect investor confidence.
FAQ
What is the date and time of Seres Therapeutics' presentation at the J.P. Morgan Healthcare Conference?
Seres Therapeutics will present on January 16, 2025, at 7:30 a.m. PT.
What is SER-155 and why is it significant?
SER-155 is Seres' lead program, recently receiving Breakthrough Therapy designation for reducing bloodstream infections in certain patients.
How did SER-155 perform in clinical studies?
In Phase 1b studies, SER-155 showed a 77% relative risk reduction in bloodstream infections compared to placebo.
What populations are being targeted for SER-155 development?
SER-155 targets medically vulnerable populations, including patients undergoing allogeneic and autologous stem cell transplants and cancer patients.
Where can I access the live webcast of the presentation?
The live video webcast will be available on Seres Therapeutics' website under the “Events and Presentations” section.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MCRB Insider Trading Activity
$MCRB insiders have traded $MCRB stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $MCRB stock by insiders over the last 6 months:
- MATTHEW R. HENN (See Remarks) has traded it 3 times. They made 0 purchases and 3 sales, selling 5,834 shares.
- ERIC D. SHAFF (CEO and President) has traded it 3 times. They made 0 purchases and 3 sales, selling 13,771 shares.
- TERESA L. YOUNG (See Remarks) has traded it 4 times. They made 0 purchases and 4 sales, selling 28,926 shares.
- MOLTKE LISA VON (See Remarks) has traded it 3 times. They made 0 purchases and 3 sales, selling 6,284 shares.
- THOMAS DESROSIER (Chief Legal Officer and EVP) has traded it 3 times. They made 0 purchases and 3 sales, selling 6,010 shares.
- DAVID S. EGE (See Remarks) sold 1,128 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MCRB Hedge Fund Activity
We have seen 24 institutional investors add shares of $MCRB stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 2,207,112 shares (-91.7%) from their portfolio in Q3 2024
- WOODLINE PARTNERS LP removed 2,045,871 shares (-100.0%) from their portfolio in Q2 2024
- HANDELSBANKEN FONDER AB removed 1,100,000 shares (-100.0%) from their portfolio in Q2 2024
- HUDSON BAY CAPITAL MANAGEMENT LP removed 1,004,978 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 755,644 shares (-42.5%) from their portfolio in Q3 2024
- JANE STREET GROUP, LLC removed 686,203 shares (-97.0%) from their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC removed 652,283 shares (-97.8%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and Chief Executive Officer, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT.
Seres will highlight its plans to advance its biotherapeutics pipeline, focusing on SER-155, the Company’s lead program. The Company recently announced that SER-155 received Breakthrough Therapy designation for the reduction of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant, to treat hematological malignancies, from the US Food and Drug Administration (FDA). This designation was supported by Phase 1b placebo-controlled study results in patients undergoing allo-HSCT demonstrating that SER-155 was associated with a significant reduction in BSIs (77% relative risk reduction), a significant reduction in systemic antibiotic exposure, and lower incidence of febrile neutropenia. In addition to allo-HSCT, bloodstream infections are a common and serious complication in many other medically vulnerable populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. Seres is actively seeking a partner to provide financial resources and other capabilities to more fully explore the development of SER-155 and additional pipeline candidates for these populations.
A live video webcast of the presentation will be accessible under the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at www.serestherapeutics.com and will be available for replay following the event.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received both Breakthrough Therapy and Fast Track designation, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit
www.serestherapeutics.com
.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: our clinical development plans; the ability for SER-155 and other product candidates to improve patient outcomes in medically vulnerable populations; our ability to secure a partnership and/or generate additional capital; and other statements which are not historical fact.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) we have incurred significant losses, are not currently profitable and may never become profitable; (2) our need for additional funding; (3) our history of operating losses; (4) our novel approach to therapeutic intervention; (5) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (6) the competition we will face; (7) our ability to protect our intellectual property; (8) our ability to retain key personnel and to manage our growth; (9) the effect of the VOWST sale on our ability to retain and hire key personnel and maintain relationships with our customers, suppliers, advertisers, partners and others with whom we do business, or on our operating results and businesses generally; (10) the risks associated with the disruption of management’s attention from ongoing business operations due to the obligation to provide transition services; (11) our failure to receive the installment payments or the milestone payments in the future; (12) the uncertainty of impact of the 50/50 profit and loss sharing arrangement on our reported results and liquidity; and (13) we may not be able to realize the anticipated benefits of the VOWST sale. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), on November 13, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor and Media Contacts:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
